The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [41] A Validation Study of HER2 Immunohistochemistry Digital Imaging Analysis and its Correlation with HER2 Fluorescence In Situ Hybridization Results in Breast Carcinoma
    Hartage, Ramon
    Li, Aidan
    Hammond, Scott
    Parwani, Anil
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1458 - 1459
  • [42] Chromogenic in situ hybridization (CISH) study of HER2 and Topo2α amplifications in metastatic breast cancer
    Todorovic-Rakovic, N.
    Neskovic-Konstantinovic, Z.
    Nikolic-Vukosavljevic, D.
    CHROMOSOME RESEARCH, 2009, 17 : 95 - 96
  • [43] Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
    Hanna, WM
    Kwok, K
    MODERN PATHOLOGY, 2006, 19 (04) : 481 - 487
  • [44] Early results of combined Her-2/neu (HER2) immunotherapy using a HER2 peptide vaccine with concurrent trastuzumab for metastatic breast cancer.
    Webster, D.
    Waisman, J.
    MacLeod, B.
    dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L.
    Disis, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S79 - S80
  • [45] Her2 amplification - Correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
    Wixom, CR
    Albers, EA
    Weidner, N
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2004, 12 (03) : 248 - 251
  • [46] The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer
    Kureyama, Nari
    Kusudo, Maho
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Nozawa, Kazuki
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [47] HER2 testing in metastatic breast cancer - is reflex in situ hybridization necessary in cases that are equivocal by immunohistochemistry?
    Liwski, C. R.
    Castonguay, M.
    Barnes, P.
    Bethune, G.
    Rayson, D.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 : S27 - S28
  • [48] Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines
    Hicks, DG
    Tubbs, RR
    HUMAN PATHOLOGY, 2005, 36 (03) : 250 - 261
  • [49] Somatic mutations of the HER2 in metastatic breast cancer
    Fang, Yi
    Jiang, Yanxia
    Wang, Xin
    Yang, Xue
    Gao, Yinqi
    Wang, Jing
    TUMOR BIOLOGY, 2014, 35 (12) : 11851 - 11854
  • [50] Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer
    Wilcock, Diane M.
    Moore, Kristina H.
    Rowe, Leslie
    Mahlow, Jonathan
    Jedrzkiewicz, Jolanta
    Cleary, Allison S.
    Lomo, Lesley
    Ruano, Ana L.
    Gering, Maarika
    Bradshaw, Derek
    Maughan, Meghan
    Tran, Phuong
    Burlingame, Jesse
    Davis, Richard
    Affolter, Kajsa
    Albertson, Daniel J.
    Adelhardt, Parisa
    Kim, Jong Take
    Coleman, Joshua F.
    Deftereos, Georgios
    Gulbahce, Evin H.
    Sirohi, Deepika
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (12) : 1402 - 1412
12345